PharmAthene, Inc. is a biodefense company developing medical countermeasures against biological and chemical threats. The company’s product candidates include: SparVax, an anthrax vaccine which has completed a Phase II clinical trial for post-exposure prophylaxis; Valortim, a human monoclonal antibody which has completed a Phase I clinical trial for the prevention and treatment of anthrax infection; and rBChE bioscavanger, a medical countermeasure for nerve agent poisoning. For more information, visit the company’s website at www.pharmathene.com.